Garry D. Johnson Joins BioClinica as Chief Technology Officer

Garry D. Johnson Joins BioClinica as Chief Technology Officer
Share Email this Article - New Position to Support Global Customer Strategy and Accelerate Growth -

NEWTOWN, Pa.-- BioClinicaTM, Inc. (NASDAQ: BIOC), a global provider of clinical trial management services, today announced the appointment of Garry D. Johnson as Senior Vice President and Chief Technology Officer (CTO), a newly created position.

BioClinica adds the position of CTO to its senior management staff to support its growth initiatives and emphasis on current and future technologies across the organization. Mr. Johnson will lead the company's global technology strategy, including developing and implementing BioClinica's technology plan, overseeing technology investments and ensuring that operational efficiencies are maximized.

Mr. Johnson comes to BioClinica with more than 15 years' experience leading international technology organizations through the strategic development and execution of business-aligned IT plans. He most recently served as Senior Vice President and Global Chief Technology officer for Dendrite International, Inc. (now Cegedim Dendrite), a global provider of sales, compliance and clinical solutions to the pharmaceutical and life sciences industry. At Dendrite Mr. Johnson led a team of 900 technology professionals on three continents tasked with delivering software and services. Among his accomplishments was the development of a new CRM solution that gained broad customer acceptance with six migrations in the first 12 months. Prior to Dendrite, Mr. Johnson held leadership positions at Boron Lepore, Inc. (now Cardinal Health) and AlliedSignal, Inc. (now Honeywell).

Mr. Johnson has had a longstanding commitment to the New Jersey Technology Council (NJTC). He was honored with NJTC's first "CIO of the Year" award in 2005. He has also served on NJTC'S CIO Advisory Board. In addition, under his leadership, Dendrite was recognized by Gartner Research Report® as "Best in Class user support for Dendrite, SAP, and Siebel users." Mr. Johnson earned a bachelor's degree in management from Fairfield University in Fairfield, CT.

"Garry is a proven technology leader with the skills to advance BioClinica's industry-leading position in clinical trial management services. His wealth of industry knowledge and experience make him a valued asset to BioClinica and our global customer base," said Mark Weinstein, CEO of BioClinica. "Adding Garry to the BioClinica team is an important benchmark in our company history. The CTO position creates a global-level perspective focused on technology innovation that is expected to maintain BioClinica's competitive edge and expand our reputation for providing best-in-class solutions."

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.